Abstract
We investigated the impact of the piperacillin-tazobactam MIC in the outcome of 39 bloodstream infections due to extended-spectrum-β-lactamase-producing Escherichia coli. All 11 patients with urinary tract infections survived, irrespective of the MIC. For other sources, 30-day mortality was lower for isolates with a MIC of ≤ 2 mg/liter than for isolates with a higher MIC (0% versus 41.1%; P = 0.02).
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Anti-Bacterial Agents / therapeutic use*
-
Bacteremia / drug therapy
-
Bacteremia / mortality
-
Cohort Studies
-
Drug Therapy, Combination
-
Enzyme Inhibitors / therapeutic use
-
Escherichia coli / drug effects*
-
Escherichia coli Infections / drug therapy*
-
Humans
-
Microbial Sensitivity Tests
-
Penicillanic Acid / analogs & derivatives*
-
Penicillanic Acid / therapeutic use
-
Piperacillin / therapeutic use
-
Piperacillin, Tazobactam Drug Combination
-
Tazobactam
-
Treatment Outcome
-
Urinary Tract Infections / drug therapy*
-
beta-Lactamases / metabolism
Substances
-
Anti-Bacterial Agents
-
Enzyme Inhibitors
-
Piperacillin, Tazobactam Drug Combination
-
Penicillanic Acid
-
beta-Lactamases
-
Tazobactam
-
Piperacillin